Exelixis, Inc. (NASDAQ:EXEL) announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell …
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the first quarter of 2016 and provided an update on progress toward delivering upon its key 2016 …
It’s an exciting week ahead for pharmaceutical companies Relypsa Inc (NASDAQ:RLYP), GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Exelixis, Inc. (NASDAQ:EXEL), as …
Sarepta Therapeutics Inc (NASDAQ:SRPT) is down over 45% in pre-market trading following a negative vote by an FDA advisory panel regarding the effectiveness …
Exelixis, Inc. (NASDAQ:EXEL) announced that the U.
Following a large drug rights purchase and an informative Mobile World Congress, analysts provide updates and share their insights on Exelixis, Inc. (NASDAQ:EXEL) …
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the fourth quarter and full year of 2015 and provided an overview of key 2016 corporate objectives …
Exelixis, Inc. (NASDAQ:EXEL) and Ipsen jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis’ lead oncology drug.
The biotech sector has had a really cruel start to the year. The Nasdaq Biotechnology Index (IBB) is down 26% so far in …
Cowen & Co healthcare analysts provide updates following successful phase three trial for Exelixis, Inc.’s (NASDAQ:EXEL) drug, Cabozantinib, and Avalanche Biotechnologies Inc’s (NASDAQ:AAVL) …
